Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Biochemistry and Molecular Biology: Katz Ehud


 Last updated December 2021 - Biochemistry and Molecular Biology 

List of Publications

(1) Blum N, Katz E, Fee E. Blum et al. respond. Am J Public Health 2011;101(5):775.

(2) Blum N, Katz E, Fee E. Professor Natan Goldblum: The pioneer producer of the inactivated poliomyelitis vaccine in Israel. Am J Public Health 2010;100(11):2074-2075.

(3) Yudovin-Farber I, Gurt I, Hope R, Domb AJ, Katz E. Inhibition of herpes simplex virus by polyamines. Antiviral Chem Chemother 2009;20(2):87-98.

(4) Charity JC, Katz E, Moss B. Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology 2007;359(1):227-232.

(5) Abdalrhman I, Gurt I, Katz E. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA). Vaccine 2006;24(19):4152-4160.

(6) Gurt I, Abdalrhman I, Katz E. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antiviral Res 2006;69(3):158-164.

(7) Katz E, Ward BM, Weisberg AS, Moss B. Mutations in the Vaccinia Virus A33R and B5R Envelope Proteins That Enhance Release of Extracellular Virions and Eliminate Formation of Actin-Containing Microvilli without Preventing Tyrosine Phosphorylation of the A36R Protein. J Virol 2003;77(22):12266-12275.

(8) Barchichat S, Katz E. Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane. Virus Res 2002;90(1-2):243-251.

(9) Katz E, Wolffe E, Moss B. Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol 2002;76(22):11637-11644.

(10) Loewinger M, Katz E. Ultraviolet-irradiated vaccinia virus recombinants, exposing HIV-envelope on their outer membrane, induce antibodies against this antigen in rabbits. Viral Immunol 2002;15(3):473-479.

(11) Hashavya S, Barchichat S, Katz E. Growth and infectivity assays of the Israeli vaccine strain of fowl poxvirus in chicken embryo fibroblasts. Avian Dis 2002;46(1):95-101.

(12) Keywan K, Katz E. The antiviral activity exerted by vaccinia virus on the growth of herpes simplex virus in BS-C-1 cells. Antiviral Res 2000;46(2):145-155.

(13) Keywan K, Katz E. Co-infection of acyclovir-resistant and acyclovir-sensitive Herpes simplex type 2 virus strains in BS-C-1 cells. Intervirology 1999;42(4):247-251.

(14) Stienlauf S, Shoresh M, Solomon A, Lublin-Tennenbaum T, Atsmon Y, Meirovich Y, et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 1999;17(3):201-204.

(15) Ifrah M, Stienlauf S, Shoresh M, Katz E. A tetrazolium-based colorimetric assay for titration of neutralizing antibodies against vaccinia virus. Viral Immunol 1998;11(1):49-54.

(16) Katz E, Moss B. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. AIDS Res Hum Retroviruses 1997;13(17):1497-1500.

(17) Wolffe EJ, Katz E, Weisberg A, Moss B. The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J Virol 1997;71(5):3904-3915.

(18) Katz E, Wolffe EJ, Moss B. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 1997;71(4):3178-3187.

(19) Breuer E, Karaman R, Zaher H, Katz E. Synthesis of some acylphosphonate thiosemicarbazones and evaluation of their antiviral activity. Drug Des Discov 1994;11(1):39-46.

(20) Garuti L, Ferranti A, Ronerti M, Katz E, Budriesi R, Chiarini A. Synthesis and biological evaluation of some new phosphonates. Pharmazie 1992;47(4):295-297.

(21) Katz E, Rosenblat O, Pisanty S. Isolation and characterization of herpes simplex virus resistant to nucleoside analogs. Oral Surg Oral Med Oral Pathol 1991;72(3):296-299.

(22) Ei-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990;161(3):446-448.

(23) Lublin-Tennenbaum T, Katzenelson E, El-Ad B, Katz E. Correlation between cutaneous reaction in vaccinees immunized against smallpox and antibody titer determined by plaque neutralization test and ELISA. Viral Immunol 1990;3(1):19-25.

(24) Slosaris M, Levy B, Katz E, Levy R, Zakay-Rones Z. Elevated virulence of Newcastle disease virus strains following serial passages in kidney cells in vitro. Avian Dis 1989;33(2):248-253.

(25) Katz E, Samid D. Transfection of EK-3, a subline of NIH 3T3, with the oncogene Ha-ras does not abolish its anchorage dependence. Eur J Cell Biol 1989;49(2):221-224.

(26) Katz E. Thiosemicarbazones: Inhibition of the growth of pox viruses and requirement for the growth of an isatin-β-thiosemicarbazone dependent mutant. J Basic Clin Physiol Pharmacol 1987;6(2):119-130.

(27) Katz E. Heterogeneity in transformation efficiency of NIH 3T3 cells as determined by transfection with oncogenes. Eur J Cell Biol 1986;42(2):231-235.

(28) Katz E, Carter BJ. Effect of Adeno-Associated Virus on Transformation of Nih 3T3 Cells by Ras Gene and on Tumorigenicity of an NIH 3T3 Transformed Cell Line. Cancer Res 1986;46(6):3023-3026.

(29) Katz E, Carter BJ. A mutant cell line derived from NIH/3T3 cells: Two oncogenes required for in vitro transformation. J Natl Cancer Inst 1986;77(4):909-914.

(30) Ferranti A, Garuti L, Giovanninetti G, Katz E. Studies on Potential Antiviral Compounds, XXIV. New 1‐substituted isatin β‐thiosemicarbazones. Arch Pharm 1985;318(5):415-421.

(31) Katz E, Margalith E. Antiviral activity of SK&F 21681 against herpes simplex virus. Antimicrob Agents Chemother 1984;25(2):195-200.

(32) Breuer E, Melumad D, Sarel So, Katz E. Antiviral compounds. 3. The preparation of some diketophosphonates derived from sugars. Eur J Med Chem 1983;18(6):487-488.

(33) Breuer E, Melumad D, Sarel S, Margalith E, Katz E. Antiviral Compounds. 1. Structure-Activity Relationship of Some Antiviral Enediones Derived from Aldehydo Sugars. J Med Chem 1983;26(1):30-34.

(34) Katz E, Margalith E. Characterization of an herpes simplex virus type 2 mutant, which is resistant to acycloguanosine and causes fusion of BSC1 cells. Arch Virol 1982;74(2-3):111-123.

(35) Katz E, Mitrani-Rosenbaum S, Margalith E, Ben-Bassat H. Interaction of herpes simplex virus with human cell lines at various stages of lymphoid differentiation. Intervirology 1981;16(1):33-42.

(36) Krempien U, Schneider L, Hiller G, Weber K, Katz E, Jungwirth C. Conditions for pox virus-specific microvilli formation studied during synchronized virus assembly. Virology 1981;113(2):556-564.

(37) Katz E, Margalith E. Inhibition of vaccinia virus maturation by zinc chloride. Antimicrob Agents Chemother 1981;19(2):213-217.

(38) Zakay-Rones Z, Margalith E, Levy R, Katz E. A sensitive plaque inhibition technique for assay of antibodies to influenza virus: Use to detect previous antigenic priming with influenza viruses. J Virol Methods 1980;1(6):355-360.

(39) Katz E, Margalith E, Duksin D. Antiviral activity of tunicamycin on herpes simplex virus. Antimicrob Agents Chemother 1980;17(6):1014-1022.

(40) Cooper JA, Moss B, Katz E. Inhibition of vaccinia virus late protein synthesis by isatin-β-thiosemicarbazone: Characterization and in vitro translation of viral mRNA. Virology 1979;96(2):381-392.

(41) Katz E, Margalith E, Winer B. Genetic recombination between a temperature sensitive mutant and an isatin β thiosemicarbazone (IBT) resistant mutant of vaccinia virus. J Antimicrob Chemother 1978;4(2):159-162.

(42) Katz E, Margalith E, Winer B. Formation of vaccinia virus DNA-protein complex in the presence of isatin β thiosemicarbazone (IBT). J Gen Virol 1978;40(3):695-699.

(43) Katz E, Felix H. Synthesis of vaccinia viral antigens in HeLa cells in the presence of isatin beta thiosemicarbazone. Antimicrob Agents Chemother 1977;11(2):202-208.

(44) Katz E, Margalith E, Winer B. Structure activity relationships of thiosemicarbazones on vaccinia virus and IBT-dependent mutant. J Antimicrob Chemother 1976;2(3):255-260.

(45) Katz E, Margalith E, Winer B. The effect of tilorone hydrochloride on the growth of several animal viruses in tissue cultures. J Gen Virol 1976;31(1):125-129.

(46) Katz E, Margalith E, Winer B. Inhibition of vaccinia virus growth by the nucleoside analogue 1 β d ribofuranosyl 1,2,4 triazole 3 carboxamide (Virazole, Ribavirin). J Gen Virol 1976;32(2):327-330.

(47) Katz E, Margalith E, Winer B. Inhibition of herpesvirus deoxyribonucleic acid and protein synthesis by tilorone hydrochloride. Antimicrob Agents Chemother 1976;9(1):189-195.

(48) Katz E, Margalith E, Winer B. Isolation and characterization of a γ thiochromanone 4 thiosemicarbazone resistant mutant of vaccinia virus. Antimicrob Agents Chemother 1975;7(1):85-90.

(49) Katz E, Margalith E, Winer B. Proceedings: Effects of isatin beta-thiosemicarbazone-related compounds on vaccinia virus strains. Isr J Med Sci 1975;11(11):1209-1210.

(50) Katz E, Margalith E, Winer B. Inhibition of the growth of hemadsorption 2 virus by three acyl derivatives of amino acids. Antimicrob Agents Chemother 1975;7(5):717-718.

(51) Katz E, Margalith E, Winer B. Synthesis of vaccinia virus polypeptides in the presence of hydroxyurea. Antimicrob Agents Chemother 1974;6(5):647-650.

(52) Katz E, Margalith E, Winer B. The effect of isatin β thiosemicarbazone (IBT) related compounds on IBT resistant and on IBT dependent mutants of vaccinia virus. J Gen Virol 1974;25(2):239-244.

(53) Katz E, Margalith E. Location of rous sarcoma viral structural polypeptides on the virion surface. Archiv f Virusforschung 1973;41(3):290-294.

(54) Katz E, Margalith E, Winer B, Lazar A. Characterization and mixed infections of three strains of vaccinia virus: Wild type, IBT resistant and IBT dependent mutants. J Gen Virol 1973;21(3):469-475.

(55) Katz E, Margalith E, Winer B. An isatin β thiosemicarbazone (IBT) dependent mutant of vaccinia virus: the nature of the IBT dependent step. J Gen Virol 1973;21(3):477-484.

(56) Katz E, Margalith E, Winer B, Goldblum N. Synthesis of vaccinia virus polypeptides in the presence of isatin-beta-thiosemicarbazone. Antimicrob Agents Chemother 1973;4(1):44-48.

(57) Katz E, Winer B, Margalith E, Goldblum N. Isolation and characterization of an IBT-dependent mutant of vaccinia virus. J Gen Virol 1973;19(1):161-164.

(58) Katz E, Margalith E. Location of vaccinia virus structural polypeptides on the surface of the virus particle. J Gen Virol 1973;18(3):381-384.

(59) Katz ER, Sussman M. Parasexual recombination in Dictyostelium discoideum: selection of stable diploid heterozygotes and stable haploid segregants (clones-temperature sensitive-ploidy-fruiting bodies-spore-slime mold). Proc Natl Acad Sci U S A 1972;69(2):495-498.

(60) Weiss RA, Friis RR, Katz E, Vogt PK. Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virology 1971;46(3):920-938.

(61) Katz E, Vogt PK. Conditional lethal mutants of avian sarcoma viruses. II. Analysis of the temperature-sensitive lesion in ts 75. Virology 1971;46(3):745-753.

(62) Katz E, Grimley P, Moss B. Reversal of anti-viral effects of rifampicin. Nature 1970;227(5262):1050-1051.

(63) Katz E, Moss B. Vaccinia virus structural polypeptide derived from a high-molecular-weight precursor: formation and integration into virus particles. J Virol 1970;6(6):717-726.

(64) Katz E, Moss B. Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin. Proc Natl Acad Sci U S A 1970;66(3):677-684.

(65) Moss B, Rosenblum EN, Katz E, Grimley PM. Rifampicin : A specific inhibitor of vaccinia virus assembly. Nature 1969;224(5226):1280-1284.

(66) Moss B, Katz E, Rosenblum EN. Vaccinia virus directed RNA and protein synthesis in the presence of rifampicin. Biochem Biophys Res Commun 1969;36(5):858-865.

(67) Moss B, Katz E. Synthesis of vaccinia viral proteins in cytoplasmic extracts. II. Identification of early and late viral proteins. J Virol 1969;4(5):596-602.

(68) Katz E, Moss B. Synthesis of vaccinia viral proteins in cytoplasmic extracts. I. Incorporation of radioactively labeled amino acids into polypeptides. J Virol 1969;4(4):416-422.

(69) Katz E, Goldblum N. Isolation of an "antigenic variant" of West Nile virus, originating from a chronic infection of the virus in LLC cells. Isr J Med Sci 1968;4(4):911-913.

(70) Katz E, Goldblum N. Establishment, steady state and cure of a chronic infection of LLC cells with West Nile Virus. Archiv f Virusforschung 1968;25(1):69-82.

(71) Katz E, Goldblum N. Selection of a "Temperature" resistant mutant of west nile virus. Archiv f Virusforschung 1968;25(1):65-68.

(72) Katz E, Goldblum T, Bachrach U, Goldblum N. Antiviral action of oxidized spermine: inactivation of certain animal viruses. Isr J Med Sci 1967;3(4):575-577.